 SAN DIEGO, April 10, 2021 PRNewswire -- MEI Pharma, Inc. NASDAQ: MEIP, a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase CDK inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors. The research is featured as an E-Poster Session presentation titled, Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models at the American Association for Cancer Research AACR Annual Meeting 2021. 